Aletheia Capital raises Nvidia stock price target on AI chip demand

Aletheia Capital raised Nvidia’s price target to $270 from $250 and kept a Buy rating, while lifting fiscal 2028 revenue and earnings estimates by 32% and 25% on $1 trillion guidance tied to Blackwell, Rubin, Vera and LPX. The firm expects Q1 fiscal 2027 results and guidance to beat Bloomberg consensus by $2 billion to $3 billion, with additional upside from AI capex trends and potential China/H200-related revenue. Multiple other firms also lifted targets, reinforcing a constructive outlook for NVDA.

Analysis

The important read-through is not that the street is getting more constructive on NVDA; it is that the demand curve is still accelerating faster than supply normalization can absorb. If hyperscaler capex remains sticky and model-training intensity keeps rising, the next leg is likely driven by packaging, HBM, and advanced-node bottlenecks rather than pure GPU unit growth, which means margin upside can persist even if top-line beats become more anticipated. That also implies supplier power is shifting deeper into the stack, favoring the few component vendors with constrained capacity and pricing discipline.

The second-order risk is that the market may be underestimating how much of the current re-rating depends on a narrow set of AI spenders keeping budgets elevated into 2026. A pause in cloud capex would hit NVDA first, but it would also reverberate into memory, foundry, substrate, and networking names that have been pricing in a multi-quarter capacity supercycle. China is an upside optionality, not a base case; any incremental revenue there is more likely to show up as lumpy upside than a reliable guidance bridge, so investors should not pay for it twice.

The more interesting contrarian issue is valuation durability: once a stock trades on a long-dated earnings multiple anchored to 2027-2028, any disappointment in product transition timing or gross margin stability can compress the multiple faster than estimates can rise. In other words, the stock can still go higher, but the risk/reward becomes more asymmetric around execution cadence than around headline AI demand. The cleanest way to think about this is that NVDA remains a quality compounder, but the trade is increasingly about whether the company can keep converting demand visibility into incremental margin rather than simply beating consensus.

Key Decisions for Investors

• Stay long NVDA into the next print, but use call spreads rather than outright stock for the next 4-8 weeks; the catalyst path is positive, but upside is more likely to come from a beat-and-raise than a multiple re-rating from here.
• Pair long NVDA / short a basket of AI infrastructure laggards with weaker pricing power over the next 1-2 months; the names most exposed to supply chain relief should underperform if NVDA confirms continued bottlenecks and demand strength.
• Add selectively to HBM/memory and advanced packaging suppliers on any pullback over the next 2-3 months; the second-order beneficiaries are likely to retain pricing power even if NVDA’s multiple stabilizes.
• Use downside hedges in the 1-3 month window via NVDA put spreads around earnings/guidance events; the key risk is not demand collapse but any sign of margin pressure from memory costs or delayed product ramps.
• Avoid paying for China upside in base-case underwriting; treat any incremental revenue from export approvals as a tactical trade, not a core long-term thesis, because it remains the least controllable part of the model.